PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29386360-0	2018	Therapeutic synergy between tigecycline and venetoclax in a preclinical model of MYC/BCL2 double-hit B cell lymphoma.	Tigecycline	28-39	B cell leukemia/lymphoma 2	Mus musculus	85-89	
29386360-4	2018	BCL2 activation in mouse Emu-myc lymphomas antagonized tigecycline-induced cell death, which was specifically restored by combined treatment with the BCL2 inhibitor venetoclax.	Tigecycline	55-66	B cell leukemia/lymphoma 2	Mus musculus	150-154	
29386360-4	2018	BCL2 activation in mouse Emu-myc lymphomas antagonized tigecycline-induced cell death, which was specifically restored by combined treatment with the BCL2 inhibitor venetoclax.	Tigecycline	55-66	B cell leukemia/lymphoma 2	Mus musculus	0-4